Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab
Background. Despite the proven efficacy and safety of biologics in the treatment of psoriasis (Ps), a number of patients experience heterogeneity in response to therapy in both the short-term and long-term perspectives. Aims. To identify correlations between the blood cytokine levels, clinical se...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2025-03-01
|
| Series: | Vestnik Dermatologii i Venerologii |
| Subjects: | |
| Online Access: | https://vestnikdv.ru/jour/article/viewFile/16814/pdf_1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849328084294041600 |
|---|---|
| author | Arfenya E. Karamova Anastasiia A. Vorontsova Alexandr А. Nikonorov Evgenia R. Nikonorova Аlexey A. Kubanov |
| author_facet | Arfenya E. Karamova Anastasiia A. Vorontsova Alexandr А. Nikonorov Evgenia R. Nikonorova Аlexey A. Kubanov |
| author_sort | Arfenya E. Karamova |
| collection | DOAJ |
| description | Background. Despite the proven efficacy and safety of biologics in the treatment of psoriasis (Ps), a number of patients experience heterogeneity in response to therapy in both the short-term and long-term perspectives.
Aims. To identify correlations between the blood cytokine levels, clinical severity indices and the effectiveness of the IL-12/IL-23 inhibitor (ustekinumab) therapy.
Methods. The study enrolled 25 patients with psoriasis. The severity of the disease was assessed using PASI, BSA, sPGA. The clinical efficacy of ustekinumab was determined by the percentage of PASI reduction: good response(≥90) moderate response (≥75) and low efficacy (≤50). Blood cytokine levels were determined by multiplex immunological analysis (xMAP) technology. Statistical analysis was performed using RStudio and the R programming language.
Results. Moderate Ps was diagnosed in 15 patients (60%), severe — in 10 (40%). The baseline levels of IL31, sCD40L and VEGF were respectively 2.3 (p = 0.018),2.3 (p = 0.010), and 2.0 (p = 0.033) times higher in severe Ps. By the 16th week, therapy was effective in 92% of patients and was accompanied by a 3.47 fold decrease in IL-31 (p = 0.002) and an increase in ICAM1 and VEGF by 35.8% (p = 0.026) and 4.2 times (p 0.001) respectively. A correlation between ∆PASI and IL-12, IL-17F, IL-20, IL-22, IL-31, sCD40L, VEGF was found. Ustekinumab significantly modified cytokine interactions and neutralized their correlation with ∆PASI.
Conclusion. IL-31, sCD40L and VEGF baseline levels correlate with Ps severity, IL-17F, IL-20 and IL-31 — with ∆PASI, demonstrating their potential use in objectively determining Ps severity and predicting the ustekinumab therapy effectiveness. |
| format | Article |
| id | doaj-art-ae05e47af88a4ff79e519d3dc7af15e5 |
| institution | Kabale University |
| issn | 0042-4609 2313-6294 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | State Scientific Center of Dermatovenereology and Cosmetology |
| record_format | Article |
| series | Vestnik Dermatologii i Venerologii |
| spelling | doaj-art-ae05e47af88a4ff79e519d3dc7af15e52025-08-20T03:47:41ZengState Scientific Center of Dermatovenereology and CosmetologyVestnik Dermatologii i Venerologii0042-46092313-62942025-03-011011505810.25208/vdv168141324Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumabArfenya E. Karamova0https://orcid.org/0000-0003-3805-8489Anastasiia A. Vorontsova1https://orcid.org/0000-0002-3129-0050Alexandr А. Nikonorov2https://orcid.org/0000-0001-7214-8176Evgenia R. Nikonorova3https://orcid.org/0000-0002-6360-2194Аlexey A. Kubanov4https://orcid.org/0000-0002-7625-0503State Research Center of Dermatovenereology and CosmetologyState Research Center of Dermatovenereology and CosmetologyState Research Center of Dermatovenereology and CosmetologyState Research Center of Dermatovenereology and CosmetologyState Research Center of Dermatovenereology and CosmetologyBackground. Despite the proven efficacy and safety of biologics in the treatment of psoriasis (Ps), a number of patients experience heterogeneity in response to therapy in both the short-term and long-term perspectives. Aims. To identify correlations between the blood cytokine levels, clinical severity indices and the effectiveness of the IL-12/IL-23 inhibitor (ustekinumab) therapy. Methods. The study enrolled 25 patients with psoriasis. The severity of the disease was assessed using PASI, BSA, sPGA. The clinical efficacy of ustekinumab was determined by the percentage of PASI reduction: good response(≥90) moderate response (≥75) and low efficacy (≤50). Blood cytokine levels were determined by multiplex immunological analysis (xMAP) technology. Statistical analysis was performed using RStudio and the R programming language. Results. Moderate Ps was diagnosed in 15 patients (60%), severe — in 10 (40%). The baseline levels of IL31, sCD40L and VEGF were respectively 2.3 (p = 0.018),2.3 (p = 0.010), and 2.0 (p = 0.033) times higher in severe Ps. By the 16th week, therapy was effective in 92% of patients and was accompanied by a 3.47 fold decrease in IL-31 (p = 0.002) and an increase in ICAM1 and VEGF by 35.8% (p = 0.026) and 4.2 times (p 0.001) respectively. A correlation between ∆PASI and IL-12, IL-17F, IL-20, IL-22, IL-31, sCD40L, VEGF was found. Ustekinumab significantly modified cytokine interactions and neutralized their correlation with ∆PASI. Conclusion. IL-31, sCD40L and VEGF baseline levels correlate with Ps severity, IL-17F, IL-20 and IL-31 — with ∆PASI, demonstrating their potential use in objectively determining Ps severity and predicting the ustekinumab therapy effectiveness.https://vestnikdv.ru/jour/article/viewFile/16814/pdf_1psoriasisblood cytokinescytokine networkpsoriatic arthritisil-12/il-23 inhibitor ustekinumab |
| spellingShingle | Arfenya E. Karamova Anastasiia A. Vorontsova Alexandr А. Nikonorov Evgenia R. Nikonorova Аlexey A. Kubanov Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab Vestnik Dermatologii i Venerologii psoriasis blood cytokines cytokine network psoriatic arthritis il-12/il-23 inhibitor ustekinumab |
| title | Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab |
| title_full | Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab |
| title_fullStr | Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab |
| title_full_unstemmed | Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab |
| title_short | Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab |
| title_sort | blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the il 12 il 23 inhibitor ustekinumab |
| topic | psoriasis blood cytokines cytokine network psoriatic arthritis il-12/il-23 inhibitor ustekinumab |
| url | https://vestnikdv.ru/jour/article/viewFile/16814/pdf_1 |
| work_keys_str_mv | AT arfenyaekaramova bloodcytokinesaspotentialpredictorsoftherapyeffectivenessinpatientswithmoderatetoseverepsoriasistreatedwiththeil12il23inhibitorustekinumab AT anastasiiaavorontsova bloodcytokinesaspotentialpredictorsoftherapyeffectivenessinpatientswithmoderatetoseverepsoriasistreatedwiththeil12il23inhibitorustekinumab AT alexandranikonorov bloodcytokinesaspotentialpredictorsoftherapyeffectivenessinpatientswithmoderatetoseverepsoriasistreatedwiththeil12il23inhibitorustekinumab AT evgeniarnikonorova bloodcytokinesaspotentialpredictorsoftherapyeffectivenessinpatientswithmoderatetoseverepsoriasistreatedwiththeil12il23inhibitorustekinumab AT alexeyakubanov bloodcytokinesaspotentialpredictorsoftherapyeffectivenessinpatientswithmoderatetoseverepsoriasistreatedwiththeil12il23inhibitorustekinumab |